GlaxoSmithKline Receives Hold Rating from Deutsche Bank (GSK)
Shares of GlaxoSmithKline traded up 0.43% during mid-day trading on Friday, hitting $44.22. GlaxoSmithKline has a one year low of $41.68 and a one year high of $47.70. The stock’s 50-day moving average is currently $44.93. The company has a market cap of $106.7 billion and a P/E ratio of 14.97.
A number of other analysts have also recently weighed in on GSK. Analysts at Credit Suisse reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Friday. Separately, analysts at Bank of America reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Thursday. Finally, analysts at Morgan Stanley downgraded shares of GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research note to investors on Thursday.
Ten research analysts have rated the stock with a buy rating, one has assigned an overweight rating, seventeen have issued a hold rating, two have given an underweight rating, and two have assigned a sell rating to the company’s stock. The stock presently has a consensus rating of “hold” and a consensus price target of $46.65.
The company also recently announced a quarterly dividend, which is scheduled for Thursday, April 11th. Stockholders of record on Friday, February 22nd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Wednesday, February 20th.
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.